Fulcrum Therapeutics, Inc. (FULC) › Cash & EquivalentsFulcrum Therapeutics, Inc. (FULC) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2018: $72.80M2019: $96.71M2020: $57.05M2021: $35.41M2022: $35.10M2023: $25.56M2024: $58.21M2025: $197.53M$197.53M2018Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$197.53M+239.3%2024$58.21M+127.7%2023$25.56M-27.2%2022$35.10M-0.9%2021$35.41M-37.9%2020$57.05M-41.0%2019$96.71M+32.9%2018$72.80M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share